Literature DB >> 27307580

Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Thomas J Gardner1, Domenico Tortorella2.   

Abstract

The prototypic herpesvirus human cytomegalovirus (CMV) exhibits the extraordinary ability to establish latency and maintain a chronic infection throughout the life of its human host. This is even more remarkable considering the robust adaptive immune response elicited by infection and reactivation from latency. In addition to the ability of CMV to exist in a quiescent latent state, its persistence is enabled by a large repertoire of viral proteins that subvert immune defense mechanisms, such as NK cell activation and major histocompatibility complex antigen presentation, within the cell. However, dissemination outside the cell presents a unique existential challenge to the CMV virion, which is studded with antigenic glycoprotein complexes targeted by a potent neutralizing antibody response. The CMV virion envelope proteins, which are critical mediators of cell attachment and entry, possess various characteristics that can mitigate the humoral immune response and prevent viral clearance. Here we review the CMV glycoprotein complexes crucial for cell attachment and entry and propose inherent properties of these proteins involved in evading the CMV humoral immune response. These include viral glycoprotein polymorphism, epitope competition, Fc receptor-mediated endocytosis, glycan shielding, and cell-to-cell spread. The consequences of CMV virion glycoprotein-mediated immune evasion have a major impact on persistence of the virus in the population, and a comprehensive understanding of these evasion strategies will assist in designing effective CMV biologics and vaccines to limit CMV-associated disease.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27307580      PMCID: PMC4981668          DOI: 10.1128/MMBR.00018-16

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  180 in total

Review 1.  Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.

Authors:  Peter A Andrews; Vincent C Emery; Chas Newstead
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

2.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.

Authors:  D R Gretch; B Kari; L Rasmussen; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients.

Authors:  Elisabeth Puchhammer-Stöckl; Irene Görzer; Alexander Zoufaly; Peter Jaksch; Claudia C Bauer; Walter Klepetko; Therese Popow-Kraupp
Journal:  Transplantation       Date:  2006-01-27       Impact factor: 4.939

4.  High variability of cytomegalovirus glycoprotein B gene and frequent multiple infections in HIV-infected patients with low CD4 T-cell count.

Authors:  U Meyer-König; B Schrage; D Huzly; A Bongarts; F T Hufert
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177

5.  Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.

Authors:  Marco Patrone; Massimiliano Secchi; Loretta Fiorina; Mariagrazia Ierardi; Gabriele Milanesi; Andrea Gallina
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  {alpha}V{beta}3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2.

Authors:  Tatiana Gianni; Valentina Gatta; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G.

Authors:  Elizabeth R Sprague; Henrike Reinhard; Evelyn J Cheung; Alexander H Farley; Robin Deis Trujillo; Hartmut Hengel; Pamela J Bjorkman
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

9.  HCMV spread and cell tropism are determined by distinct virus populations.

Authors:  Laura Scrivano; Christian Sinzger; Hans Nitschko; Ulrich H Koszinowski; Barbara Adler
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

10.  αvβ6- and αvβ8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion.

Authors:  Tatiana Gianni; Stefano Salvioli; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher; Gabriella Campadelli-Fiume
Journal:  PLoS Pathog       Date:  2013-12-19       Impact factor: 6.823

View more
  28 in total

1.  Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

Authors:  Mark R Schleiss
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-06       Impact factor: 11.205

2.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 3.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

4.  Searching for a Serological Correlate of Protection for a CMV Vaccine.

Authors:  M R Schleiss
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

5.  Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig.

Authors:  Stewart Coleman; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-06-23       Impact factor: 3.616

6.  Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys.

Authors:  Cody S Nelson; Diana Vera Cruz; Dollnovan Tran; Kristy M Bialas; Lisa Stamper; Huali Wu; Margaret Gilbert; Robert Blair; Xavier Alvarez; Hannah Itell; Meng Chen; Ashlesha Deshpande; Flavia Chiuppesi; Felix Wussow; Don J Diamond; Nathan Vandergrift; Mark R Walter; Peter A Barry; Michael Cohen-Wolkowiez; Katia Koelle; Amitinder Kaur; Sallie R Permar
Journal:  JCI Insight       Date:  2017-07-06

7.  Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.

Authors:  Nadia S El-Hamdi; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2020-06-11       Impact factor: 3.616

8.  Rat and human cytomegalovirus ORF116 encodes a virion envelope glycoprotein required for infectivity.

Authors:  Philippe Gatault; Iris K A Jones; Christine Meyer; Craig Kreklywich; Timothy Alexander; Patricia P Smith; Michael Denton; Josh Powell; Susan L Orloff; Daniel N Streblow
Journal:  Virology       Date:  2021-02-09       Impact factor: 3.616

Review 9.  Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth.

Authors:  Miranda Li; Alyssa Brokaw; Anna M Furuta; Brahm Coler; Veronica Obregon-Perko; Ann Chahroudi; Hsuan-Yuan Wang; Sallie R Permar; Charlotte E Hotchkiss; Thaddeus G Golos; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

Review 10.  Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity.

Authors:  Hsuan-Yuan Wang; Sarah M Valencia; Susanne P Pfeifer; Jeffrey D Jensen; Timothy F Kowalik; Sallie R Permar
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.